Heart failure with preserved ejection fraction

References

• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16) e147-239
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 Update: a report from the American Heart Association. Circulation 2014;129(3):399-410
   PubMed Web of Science ®Google Scholar
• Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47(5):320-32
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194-202
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007;153(6):1021-8
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355(3):260-9
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251-9
   PubMed Web of Science ®Google Scholar
• Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350(19):1953-9
   Web of Science ®Google Scholar
• Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105(11):1387-93
   PubMed Web of Science ®Google Scholar
• Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004;351(11):1097-105
   PubMedGoogle Scholar
• Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003;41(9):1519-22
   PubMed Web of Science ®Google Scholar
• Borbely A, Van Der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005;111(6):774-81
   PubMed Web of Science ®Google Scholar
• Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014;7(1):104-15
   Google Scholar
• Lewinter MM, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: if it’s not one thing it’s another. Circ Heart Fail 2013;6(6):1112-15
   Google Scholar
• Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011;124(23):2491-501
   Web of Science ®Google Scholar
• Van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113(16):1966-73
   PubMed Web of Science ®Google Scholar
• Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115(7):888-95
   PubMed Web of Science ®Google Scholar
• Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011;4(3):246-56
   PubMed Web of Science ®Google Scholar
• Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4(1):44-52
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002;34(12):1585-93
   Google Scholar
• Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000;47(2):274-83
   Google Scholar
• Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114(20):2138-47
   PubMed Web of Science ®Google Scholar
• Phan TT, Shivu GN, Abozguia K, et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010;3(1):29-34
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62(4):263-71
   PubMed Web of Science ®Google Scholar
• Mckee PA, Castelli WP, Mcnamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285(26):1441-6
   PubMed Web of Science ®Google Scholar
• Mcmurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8). 803-69
   PubMed Web of Science ®Google Scholar
• Maisel AS, Mccord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41(11):2010-17
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22(2):107-33
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2013;311(5) 507-20
   Google Scholar
• Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994;90(6):2761-71
   Google Scholar
• Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27(19):2338-45
   PubMed Web of Science ®Google Scholar
• Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010;3(4):477-85
   Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362(9386):777-81
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, Mcmurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456-67
   PubMed Web of Science ®Google Scholar
• Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6(4):453-61
   Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-25
   PubMed Web of Science ®Google Scholar
• Van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53(23):2150-8
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Hammill BG, O’connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53(2):184-92
   PubMed Web of Science ®Google Scholar
• Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32(6):865-79
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83(6):1849-65
   PubMed Web of Science ®Google Scholar
• Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004;145(7):3153-7
   Google Scholar
• Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011;17(8):634-42
   PubMed Web of Science ®Google Scholar
• Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309(8):781-91
   PubMed Web of Science ®Google Scholar
• Redfield MM, Borlaug BA, Lewis GD, et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail 2012;5(5):653-9
   Google Scholar
• Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124(2):164-74
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309(12):1268-77
   PubMed Web of Science ®Google Scholar
• O’connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301(14):1439-50
   PubMed Web of Science ®Google Scholar
• Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301(14):1451-9
   PubMed Web of Science ®Google Scholar
• Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010;3(6):659-67
   Google Scholar
• Edelmann F, Gelbrich G, Dungen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58(17):1780-91
   PubMed Web of Science ®Google Scholar
• Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008;101(3A):3-8
   PubMed Web of Science ®Google Scholar
• Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104(15):1856-62
   Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50(4):401-14
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380(9851):1387-95
   PubMed Web of Science ®Google Scholar
• Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7(2):75-82
   PubMedGoogle Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381(9860):29-39
   PubMed Web of Science ®Google Scholar
• Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2013. [Epub ahead of print]
   Google Scholar
• Kosmala W, Holland DJ, Rojek A, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013;62(15):1330-8
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33(7):1948-55
   PubMed Web of Science ®Google Scholar
• Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41(9):1510-18
   Google Scholar
• Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: a community perspective. Circ Heart Fail 2008;1(2):91-7
   Google Scholar
• Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121(12):1393-405
   PubMed Web of Science ®Google Scholar